Andrea Slattery

Andrea Slattery General Information

Biography

Ms. Andrea Slattery serves as Director of Research at Symmetry Peak. She also served as an Advisory Board Member at White Hat Capital Partners. She joined Symmetry Peak Management in January 2009 as Director of Research. From 2004 to 2008, she was one of four Senior Partners at Ardsley Partners, where she co-managed the technology portion of the approximately $1 billion long/short equity fund. Prior to her tenure at Ardsley, she was the second in command at Alkeon Capital Management LLC, a technology-focused long/short equity fund. At Alkeon, she helped to design and build the research process and team, and was directly responsible for a significant portion of both the long and short books, as the firm grew from $40 million to approximately $1.2 billion. She began her career in 1998 as a buy-side technology generalist at CIBC Oppenheimer, working with the fund and team that was later spun out to form Alkeon in 2002. She is a CFA® charter holder and graduated summa cum laude with a BSBA degree from Washington University in St. Louis, Missouri. She also serves as a board member and strategic advisor to several private technology companies. Philanthropically, she serves as the Board Chair of The LAM Foundation, a non-profit organization dedicated to finding better treatments and ultimately a cure for lymphangioleiomyomatosis (LAM), a rare lung disease that affects women. Her passion is to apply her experience in the technology industry towards enhancing patient knowledge and accelerating advances in rare disease research. She is a senior investment professional with over 20 years of experience investing in public and private technology companies. Her service to The LAM Foundation included 2 full terms as Board Chair, as well as serving on both the Executive and Development Committees. She was instrumental in upgrading the Foundation's technology infrastructure and substantially raising the awareness and profile of The LAM Foundation within the rare disease community. During her tenure as Board Chair, and due to her incredible scientific leadership, The LAM Foundation received FDA approval for a safe and effective treatment for the disease, a distinction less than 7% of rare diseases can claim. Ms. Slattery's passion is to continue to apply her experience in the technology industry towards enhancing patient knowledge and accelerating advances in rare disease research.